Roche and Foundation Medicine form R&D, commercial collaboration
Concurrent with receiving over $1bn in exchange for its majority stake, Foundation Medicine Inc. (FMI) signed a broad five-year R&D agreement with Roche focused on molecular information and genomic analysis products for cancer.
- In Vitro Diagnostics
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Technologies
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.